Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Neurocrine (NBIX – Research Report), retaining the price target of $168.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Andrew Fein’s rating is based on a combination of factors that highlight the potential growth and strong performance of Neurocrine. The company’s drug, Crenessity, has shown impressive efficacy and ease of use, leading to early sales and adoption. Despite conservative forecasts for Ingrezza, its sales slightly exceeded expectations, indicating a positive outlook for 2025. This success is attributed to higher patient uptake and improved reimbursement strategies.
Furthermore, Crenessity’s sales significantly surpassed expectations, with a notable number of new patient start forms and substantial reimbursement coverage. The drug’s adoption, especially in the pediatric and adolescent segments, underscores its importance for patients with unmet needs. Additionally, the initiation of the Phase 3 trial for osavampator in major depressive disorder, with its unique trial design, supports the company’s innovative approach. Collectively, these factors suggest a promising growth trajectory for Neurocrine, justifying the Buy rating.
In another report released today, Piper Sandler also maintained a Buy rating on the stock with a $154.00 price target.